港股異動 | 利好疊加 科濟藥業-B(2171.HK)大漲超11%再創新高
格隆匯9月3日丨昨日大漲10%的科濟藥業-B(2171.HK)再度拉昇漲超11%,高見48.65港元創歷史新高價,總市值達274億港元。近日CT053北美關鍵II期試驗已完成首例受試者入組及給藥,是少數進入該階段的中國藥企自主研發的CAR-T產品。公司相信CT053作為具有經改良、全人抗的BCMACAR-T候選產品具有令人鼓舞的療效。另外,公司中期研發開支增41%,將大幅擴張產能。公司的研發活動持續在專業領域創造數量可觀的知識產權。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.